A/Prof. Branford       Prof. Hughes

Session 3: High risk CML

• Mechanisms of resistance to TKI therapy 
  (A/Prof. Susan Branford)
• When frontline TKI therapy fails
  (Prof. Timothy Hughes)

Mechanisms of Resistance to TKI Therapy

A./Prof. Susan Branford - Centre for Cancer & Biology, Universities of Adelaide and South Australia

• BCR-ABL 1 mutations as the most common mechanism of resistance
• BCR-ABL 1 mutations as indicator for complete non-adherence to therapy
• Importance of long-term molecular monitoring to monitor adherence
• Inherited factors to modify response to TKI's
• Predictors of primary imatinib resistance

When Frontline TKI Therapy Fails
Prof. Timothy Hughes - SA Pathology, University of Adelaide

• Comparative efficacy after failure of 2nd generation TKI's
• Consensus of expert opinion on TKI nextline choices
• Selecting the best TKI after failure of 2nd generation TKI's
• Adherence and molecular response
• Characteristic BCR-ABL 1 kinetics in clinical situations
• Case studies